Tech Company Financing Transactions

Sojournix Funding Round

Sojournix, operating out of Waltham, raised $44 million from Boxer Capital, Frazier Healthcare Partners and Janus Henderson Investors.

Transaction Overview

Company Name
Announced On
1/4/2019
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series C
Investors

Boxer Capital

Frazier Healthcare Partners (Jamie Topper)

Janus Henderson Investors

RA Capital

Venrock

Proceeds Purpose
Proceeds from the financing will be used to advance SJX-653, a novel, potent, and selective neurokinin-3 (NK3) receptor antagonist in clinical development as a once-daily non-hormonal treatment for menopausal vasomotor symptoms (commonly referred to as hot flashes).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Totten Pond Rd. 110
Waltham, MA 02451
USA
Email Address
Overview
Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women's health and neuroendocrine disorders. We are advancing SJX-653, a novel, potent, selective NK3 antagonist in clinical development as a once-daily non-hormonal therapy for moderate to severe vasomotor symptoms due to menopause.
Profile
Sojournix LinkedIn Company Profile
Social Media
Sojournix Company Twitter Account
Company News
Sojournix News
Facebook
Sojournix on Facebook
YouTube
Sojournix on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Daniel Grau
  Daniel Grau LinkedIn Profile  Daniel Grau Twitter Account  Daniel Grau News  Daniel Grau on Facebook
Chief Financial Officer
Karen Roberts
  Karen Roberts LinkedIn Profile  Karen Roberts Twitter Account  Karen Roberts News  Karen Roberts on Facebook
VP - Operations
Jennifer Cormier
  Jennifer Cormier LinkedIn Profile  Jennifer Cormier Twitter Account  Jennifer Cormier News  Jennifer Cormier on Facebook
VP - Product Management
Philip Graham
  Philip Graham LinkedIn Profile  Philip Graham Twitter Account  Philip Graham News  Philip Graham on Facebook
VP - Regulatory Affairs
Ann Robbins
  Ann Robbins LinkedIn Profile  Ann Robbins Twitter Account  Ann Robbins News  Ann Robbins on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/4/2019: Ostara Nutrient Recovery Technologies venture capital transaction
Next: 1/4/2019: Immusoft venture capital transaction

 

Share this article

 


About Database of VC Transactions

Our team works diligently to document tech company VC transactions. VC transactions reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary